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Abstract
Background: MicroRNAs (miRNAs) have been recently detected in the circulation of cancer patients, where they
are associated with clinical parameters. Discovery profiling of circulating small RNAs has not been reported in
breast cancer (BC), and was carried out in this study to identify blood-based small RNA markers of BC clinical
outcome.
Methods: The pre-treatment sera of 42 stage II-III locally advanced and inflammatory BC patients who received
neoadjuvant chemotherapy (NCT) followed by surgical tumor resection were analyzed for marker identification by
deep sequencing all circulating small RNAs. An independent validation cohort of 26 stage II-III BC patients was
used to assess the power of identified miRNA markers.
Results: More than 800 miRNA species were detected in the circulation, and observed patterns showed association
with histopathological profiles of BC. Groups of circulating miRNAs differentially associated with ER/PR/HER2 status and
inflammatory BC were identified. The relative levels of selected miRNAs measured by PCR showed consistency with
their abundance determined by deep sequencing. Two circulating miRNAs, miR-375 and miR-122, exhibited strong
correlations with clinical outcomes, including NCT response and relapse with metastatic disease. In the validation
cohort, higher levels of circulating miR-122 specifically predicted metastatic recurrence in stage II-III BC patients.
Conclusions: Our study indicates that certain miRNAs can serve as potential blood-based biomarkers for NCT
response, and that miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients. These
results may allow optimized chemotherapy treatments and preventive anti-metastasis interventions in future
clinical applications.
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Background
Breast cancer (BC) is the most common cancer among
females and a leading cause of cancer death worldwide
[1]. Current clinical decision-making for BC treatment
relies on tumor characteristics and therapeutic targets
including the estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor
receptor 2 (HER2). Chemotherapy is given in the neoad-
juvant and adjuvant settings to patients with locally
advanced/high-risk primary BC as treatment for meta-
static BC leading to life-threatening parenchymal dis-
ease, or to treat endocrine resistant (ER/PR-negative)
metastatic BC [2,3]. Neoadjuvant chemotherapy (NCT)
is increasingly being used for initial treatment of locally
advanced and inflammatory BCs. Pathologic complete
response (pCR), defined as the preoperative eradication
of tumors from the breast and axillary lymph nodes [4],
is associated with optimal clinical outcome, including
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ever, conventional NCT regimens result in pCR in only
10-30% of treated BC patients [6]. In patients with resi-
dual invasive disease after NCT, a substantial proportion
experience disease progression to metastatic stage within
a few years after surgical resection. Patients with both de
novo and recurrent metastatic BC face poor prognosis,
with a median survival of 1-2 years and a 5-year survival
rate < 20% [7-9]. Development of early diagnostic mar-
kers capable of predicting a patient’s response to therapy
and recurrence with metastatic BC is therefore critical
to advancing more effective, personalized treatment. In
this study, we explored the use of circulating miRNAs
as blood-based, minimally invasive biomarkers for NCT
response and disease relapse in locally advanced and
inflammatory BC patients.
MiRNAs are naturally-occurring, non-coding small
RNA molecules of 21-24 nucleotides (nts) that form
partially complementary base pairs within the 3’
untranslated regions of protein-encoding mRNAs,
resulting in mRNA destabilization and/or translational
inhibition [10]. To date, approximately 1000 miRNAs
have been identified in humans. Compared to the large
number of mRNA genes (~30, 000 mRNAs per cell),
this relatively small number of miRNAs allows for large-
scale evaluation for individualized diagnosis and treat-
ment with higher efficiency and lower cost. Increasingly,
reports demonstrate applications of miRNAs as tissue-
based markers for the classification and prognosis of
several human cancers, including BC [11-14]. A number
of miRNAs have been found differentially expressed
between BC and normal tissues, with significant up- (e.
g., miR-21 and miR-155) or down-regulation (e.g., miR-
10b and miR-145) in cancerous tissues [12,15,16].
Expression of certain BC-related miRNAs has been cor-
related with specific biopathologic features, such as ER
and PR expression, tumor stage, vascular invasion, and
proliferation index [12,14-18].
MiRNAs are stably present in whole blood, serum,
and plasma [19,20]. Therefore, assessment of circulating
miRNA profiles from cancer patients allowing for corre-
lations between tumor traits (e.g., treatment response
and metastatic potential) and cancer-released miRNAs
are of great clinical interest. Using PCR assessments of
selected miRNAs that are reportedly dysregulated in BC,
several recent studies indicate associations of different
circulating miRNAs with primary BC, metastatic disease,
and ER status [21-25]. Microarray-based profiling has
also been carried out in pilot studies, in which certain
circulating miRNAs exhibit promising role as BC diag-
nostic markers [26,27]. Results from these previous stu-
dies, however, share limited consistency, possibly due to
the different sensitivity and specificity of the detection
approaches, as well as different patient numbers and
compositions in the study cohorts.
Because some miRNAs may exclusively exist in the
circulation with low or undetectable levels in cancer
cells, powerful discovery approaches, such as deep
sequencing analysis, may be more likely to identify diag-
nostic miRNA markers in the blood. Accordingly, we set
out to explore the potential of deep sequencing in the
current study to comprehensively analyze miRNAs that
can serve as blood-based markers for NCT response and
relapse with metastasis. As the first exploration to pro-
file circulating miRNAs in BC patients using a de novo
sequencing strategy, our study revealed global patterns
of circulating miRNAs, and led to the identification of
miRNA markers that can predict clinical outcome in
primary stage II- III BC.
Methods
Study cohort and validation cohort
The clinical and histopathological factors of the study
(training) and validation (testing) cohorts are summar-
ized in Additional file 1: Table S1. Patients at City of
Hope Medical Center (COH) had given informed con-
sent before blood sera were collected under Institutional
Review Board (IRB)-approved protocols, aliquoted and
stored at -80°C until use.
Serum specimens of the training cohort were obtained
as part of an NCT clinical trial conducted at COH.
Forty-two female stage II-III BC patients deemed appro-
priate for NCT at the time of diagnosis were collected
between December 2005 and April 2009. Upon diagno-
sis, all patients received conventional chemotherapy last-
ing 4-6 months followed by surgical resection of the
tumor. Among the 42 patients, 7 received docetaxel/
doxorubicin/cyclophosphamide (TAC) treatment regi-
men (group A), and 12 received doxorubicin/cyclopho-
sphamide (AC) treatment followed by carboplatin and
nab-paclitaxel (group B). The other 23 patients had
HER2
+ BC, and were given the same regimen as for
group B but with addition of trastuzumab (group C).
One of the HER2
+ patients was likely stage IV based on
presence of pleural effusion at diagnosis, which later
was documented to be malignant. Biopsies of the pri-
mary tumor were analyzed for pathological classification.
Upon completion of NCT, patients with Symmans resi-
dual cancer burden (RCB) score [4] of 0 were defined as
pathologic complete response (pCR), whereas those with
RCB score of ≥ 1 were defined as non-pCR. In the train-
ing cohort, 11 patients from all 3 treatment groups
relapsed with metastatic disease within 1.5 years after
serum collection, whereas the other 31 patients have not
had disease progression to date during 2-5 years of fol-
low-up. Patients with or without metastatic progression
Wu et al. Journal of Translational Medicine 2012, 10:42
http://www.translational-medicine.com/content/10/1/42
Page 2 of 10exhibit balanced age, tumor subtype, sample collection
time and treatment regimen.
For the testing cohort, patients were selected from the
COH Circulating Breast Cancer Tumor Marker Registry,
an observational cohort study that recruits women with
a variety of breast tumor histologies at the time of diag-
nosis, collects pretreatment biospecimens, and follows
them throughout their clinical course, recording patient
and tumor characteristics, treatments delivered, and
clinical outcomes. Patients who had stage II-III BC at
the time of registration who developed systemic recur-
rence while on study were defined as cases (N =9 ) .
Eight of these had sufficient serum RNA for inclusion in
the study. Controls were matched for 2:1 (N = 18) from
the remaining stage II-III BC patients who had not
developed systemic relapse on study and who had been
followed at least as long as the case. All controls had
sufficient serum RNA for the study. Other matching
characteristics included age at diagnosis, hormone
receptor and HER2 expression, and lymph node involve-
ment. These patients were recruited onto the parent
study between July 2006 and May 2010, a similar era to
the training cohort; however, as an observational cohort,
their systemic therapy regimen was determined by their
primary oncologist. Half of the patients received a simi-
lar regimen to the training cohort, including a taxane
with either doxorubicin, cyclophosphamide, and/or car-
boplatin, plus trastuzamab if their tumor was HER2
+.
The remaining individuals received a hormonal regimen
for ER
+HER2
- BC. All therapies were delivered in the
adjuvant rather than neoadjuvant setting; therefore,
metastatic relapse was the only measurable clinical out-
come in this group. Mean follow-up for the testing
cohort was 5.8 years.
RNA purification from serum
TRIZOL LS reagent (Invitrogen) was used to extract
total RNA from ~1.5 ml of serum, as describdi in the
manufacturer’s protocol. RNA pellet was dissolved in 10
μl of RNase-free water, and subjected to deep sequen-
cing and qRT-PCR as described below.
Solexa deep sequencing for small RNAs
Each serum sample was independently subjected to
library preparation and deep sequencing. All small
RNAs of 15-52 nts were selected and sequenced using
the Solexa system, following the manufacturer’s protocol
(Illumina Inc., San Diego, CA). Library preparation, as
well as cluster generation and deep sequencing, was per-
formed according to the 5’ ligation-dependent (5’ mono-
phosphate-dependent) manufacturer’sp r o t o c o l( D i g i t a l
Gene Expression for small RNA; Illumina). For each
sample, 5 μl of total RNA extracted from serum was
used for small RNA library preparation. Small RNAs
were size-selected between 17 and 52 nt according to
the single-stranded DNA marker in the small RNA
sequencing kit (Illumina). The library was quantified
using picoGreen and qPCR. Sequencing was performed
on a Genome Analyzer IIx (Illumina), and image proces-
sing and base calling were conducted using Illumina’s
pipeline.
MiRNA-directed and genome-wide interrogation of
identified sequences
Sequenced reads from Solexa were first mapped onto
human genome version hg18 using novoalign software
and the expression level of mature miRNAs in the miR-
Base human miRNA database v15 was summarized as
described before [28]. Normalization and identification
of differentially expressed miRNAs between groups were
carried out using Bioconductor package “edgeR” [29].
Reverse transcription (RT) and real time quantitative PCR
(qPCR)
For qRT-PCR assays, 5 μl of total RNA extracted from
serum was used as input into the RT reaction. RT was
carried out using the miScript Reverse Transcription Kit
(Qiagen) according to the manufacturer’s protocol. For
qPCR amplification, RT product was combined with
PCR assay reagents containing miScript Primer Assay,
Universal Primer, and SYBR Green PCR Master Mix
(Qiagen). Real-time qPCR was carried out on a BioRad
iQ5 thermocycler.
Statistical analyses
Sequence data analysis and statistical comparisons were
carried out using Bioconductor packages and an in-
house developed analysis pipeline using R statistical
environment. After mapping the deep sequencing data
onto the human genome and counting the reads for the
mature miRNAs in the miRBase database, raw miRNA
expression data were quantile normalized and log2
transformed with offset of 1. Predictive miRNA classi-
fiers for clinical outcome (the miR-375/miR-122 two-
gene signature, and each gene individually) in the NCT
training cohort was evaluated using univariate logistic
regression and leave-one-out cross-validation. Briefly,
o n es a m p l ew a sl e f to u ta st h et e s ts a m p l e ,a n dt h e
remaining 31 samples served as the training set and
used to train a univariate logistic regression model using
the two-gene signature, which was then used to predict
the status of the left out sample. If the predicted prob-
ability from the logistic regression model is more than a
cutoff determined by minimizing the prediction error
rate of training samples, the predicted status of that
sample would be assigned as “relapsed”,o r“non-
relapsed” otherwise. The predicted classification was
then compared to the observed relapse status using 2-
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calculated. This procedure was then repeated for each of
the two single gene markers. To evaluate the perfor-
mance of the two-gene signature in predicting the inde-
pendent validation cohort, the entire NCT cohort (32
samples with RT-PCR data) was used as a training set.
Odds ratio and 95% confidence internal were calculated
using univariate unconditional logistic regression to
determine if the histopathological parameters and circu-
lating miRNAs were associated with NCT response.
Results
Study design, deep sequencing and annotation strategy
To comprehensively profile all small RNA species in the
circulation, we isolated total RNA from ~1.5 ml serum
collected from BC patients at initial diagnosis (prior to
NCT), and selected small RNAs of 15-52 nts for library
preparation and deep sequencing. The profiling study
involved 42 stage II-III BC patients who participated in
a clinical trial comparing docetaxel, doxorubicin, cyclo-
phosphamide versus doxorubicin and cyclophosphamide,
followed by nab-paclitaxel and carboplatin. All patients
signed voluntary informed, IRB-approved consent forms,
and were treated with NCT at the City of Hope Medical
Center (ClinicalTrials.gov; NCT00295893). Among
them, 11 relapsed with metastatic disease progression to
stage IV during the follow-up, and the other 31 non-
progressive control cases had matched ages, tumor sub-
types and follow-up time, thus comprising the study
cohort for metastatic relapse. The 23 HER2
+ patients
received the trastuzumab-containing NCT regimen,
upon which comparable numbers of pCR (12 cases;
52%) and non-pCR (11 cases; 48%) were observed. Cor-
relation of miRNAs to NCT response and metastatic
relapse was examined (see Methods and Additional file
1: Table S1 for details).
Total sequence reads obtained from each serum sam-
ple were first aligned to human genome database
NCBI36/hg18 to overview the composition of circulating
small RNAs and to identify known RNA species. Among
aligned reads (~7-12 million) in all sequenced samples,
miRNAs represented ~50% of all read counts. Other
detected small RNA populations included tRNA (~28%),
small cytoplasmic RNA (scRNA; ~8.8%), rRNA (~4.4%),
small nuclear RNA (snRNA; ~0.6%), and small nucleolar
RNA (snoRNA; ~0.4%), etc. (Additional file 1: Figure
S1).
Identification of circulating miRNAs associated with
clinical parameters
MiRNAs were assessed and were deemed detectable if
seen in at least 2 patients. This resulted in detection of
more than 800 miRNAs, including 373 miRNAs with
sequence counts of > 50 in at least 10% of the samples
(Additional file 2: Table S2). Unsupervised hierarchical
clustering of these miRNAs detected in the circulation
separated ER
+ from ER
-cases (Figure 1A). No perfect
separation was observed between relapsed and non-
relapsed cases at the global level. The top 100 circulat-
ing miRNAs with the highest average counts among all
tested patients are indicated in Figure 1B (see Additional
file 2: Table S2 for a full list of all detected miRNAs).
These include several miRNAs that had been measured
by PCR in previous studies, such as miR-21, let-7a, miR-
155, and miR-10b, as well as miR-375 and miR-122, the
two genes we subsequently identified as outcome-asso-
ciated genes.
We next analyzed the association of each miRNA with a
given clinical parameter, i.e., status of relapse, NCT
response, ER/PR/HER2 expression or inflammatory dis-
ease. Multivariate comparison, taking into account the
different NCT regimens the patients received, led to the
identification of two miRNAs, miR-375 and miR-122,
that were differentially expressed between patients who
later developed metastatic relapse and those who did
not, with P < 0.005 and false discovery rate (FDR) < 0.1
(Table 1). Because only 2 HER2
- patients in the whole
42-patient cohort had pCR to NCT, the comparison on
treatment response was only carried out among HER2
+
patients, all of whom received the same trastuzumab-
containing NCT regimen. We identified 7 miRNAs that
were associated with NCT response (pCR vs. non-pCR)
in HER2
+ patients with FDR < 0.1 (Table 1). Of note,
miR-375 was identified in both analyses as the most sig-
nificantly different miRNA, whose prevalence in circula-
tion appeared to reflect better clinical outcome, i.e., pCR
to NCT and absence of relapse. In addition to the clini-
cal outcome, miRNAs associated with the biopathologi-
cal characteristics of primary BC were also identified. A
partial list (FDR < 0.05) of miRNAs significantly corre-
lated with the status of ER, PR, HER2 and inflammatory
BC is indicated in Table 2 (see Additional file 3: Table
S3 for a full list of all miRNAs with P < 0.05). Interest-
ingly, higher levels of circulating miR-375 were linked to
negative ER/PR status, positive HER2 status, and inflam-
matory BC, whereas higher levels of circulating miR-122
were associated with HER2-negative and non-inflamma-
tory tumors (Tables 2 and Additional file 3: S3).
PCR validation of selected miRNAs
We next selected several miRNAs, including miR-375,
miR-122, miR-184, miR-196a, miR-1, miR-410, miR-432,
and miR-16, for qRT-PCR-based validation using the
same total RNA extracts used for deep sequencing (32
out of the 42 sequenced samples had sufficient amounts
left for PCR assays). The sequencing-determined abun-
dance of these miRNAs ranged from very high (e.g.,
miR-122, ranged from 4, 683-1, 094, 999 counts with an
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Page 4 of 10Figure 1 MiRNAs detected in circulation. A. Unsupervised hierarchical clustering over all detected miRNAs. Colors in the heatmap represent a
sample’s higher (red) or lower (green) level in relation to the mean of all samples. The status of each clinical parameter was represented by
colored boxes as indicated in the figure. B. The top 100 miRNAs with the highest quantities in circulation. For each miRNA shown, the range of
normalized counts was indicated by a column, and the mean value was indicated by a line. Arrows indicate the positions of miR-122 and miR-
375 in the order of abundance.
Table 1 Circulating miRNAs associated with clinical outcome in stage II-III BC patients*
Metastatic Relapse in All patients in the Study Cohort
Relapsed Non-relapsed Log fold diff. (relapsed vs. non-relapsed)
Game name (N = 11) (N = 31) P value
Ave. counts (normalized) Ave. counts (normalized)
hsa-miR-375 2, 177 14, 316 -1.90 5.89E-05
hsa-miR-122 532, 501 168, 532 1.35 2.98E-03
NCT Response in HER2
+ Patients
pCR Non-pCR Log2 fold diff (pCR vs. non-pCR)
Game name (N = 12) (N = 11) P value
Ave. counts
(normalized)
Ave. counts
(normalized)
hsa-miR-375 32, 629 4, 014 3.02 1.10E-09
hsa-miR-184 245 31 2.99 2.59E-09
hsa-miR-1299 454 89 2.35 1.24E-06
hsa-miR-196a 989 239 2.05 1.79E-05
hsa-miR-381 384 1, 235 -1.69 2.48E-04
hsa-miR-410 129 364 -1.50 1.09E-03
hsa-miR-1246 19, 969 55, 915 -1.49 1.16E-03
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ER+ vs. ER-
Gene name ER+ (N=21) Ave. counts ER- (N=21) Ave. counts Log
2 fold diff. (ER+ vs. ER-) P value FDR
hsa-miR-375 3, 189 18, 356 -2.23 6.28E-10 3.46E-07
hsa-miR-429 58 221 -1.94 7.48E-08 1.28E-05
hsa-miR-196a 184 694 -1.92 8.14E-08 1.28E-05
hsa-miR-141* 21 75 -1.82 5.99E-07 6.59E-05
hsa-miR-376a 200 65 1.63 4.72E-06 4.33E-04
hsa-miR-370 585 198 1.56 9.98E-06 8.44E-04
hsa-miR-141 442 1, 216 -1.46 3.34E-05 2.45E-03
hsa-miR-200b 150 400 -1.42 5.82E-05 3.37E-03
hsa-miR-125a-5p 2, 222 914 -1.28 2.55E-04 1.17E-02
hsa-miR-205 83 196 -1.24 4.43E-04 1.87E-02
hsa-miR-200a 218 482 -1.14 1.11E-03 4.08E-02
hsa-miR-224 870 402 1.12 1.39E-03 4.79E-02
PR+ vs. PR-
Gene name PR
+ (N=14) Ave. counts PR- (N=28) Ave. counts Log2 fold diff. (PR
+ vs. PR-) P value FDR
hsa-miR-216a 56 17 1.75 1.20E-06 1.56E-04
hsa-miR-184 28 115 -2.03 1.28E-06 1.56E-04
hsa-miR-196a 160 578 -1.85 5.80E-06 5.28E-04
hsa-miR-370 699 238 1.55 6.24E-06 5.28E-04
hsa-miR-375 4, 457 14, 477 -1.70 2.55E-05 1.76E-03
hsa-miR-376a* 225 86 1.40 5.27E-05 3.22E-03
hsa-miR-133a 84 32 1.36 8.72E-05 4.57E-03
hsa-miR-654-5p 154 64 1.25 2.88E-04 1.29E-02
hsa-miR-125a-5p 2, 550 1077 1.24 2.93E-04 1.29E-02
hsa-miR-224 1, 028 440 1.22 3.72E-04 1.52E-02
hsa-miR-217 120 52 1.22 4.97E-04 1.89E-02
hsa-miR-429 67 176 -1.38 5.72E-04 2.10E-02
hsa-miR-494 255 114 1.16 7.86E-04 2.62E-02
hsa-miR-99b 10, 464 4934 1.08 1.56E-03 4.40E-02
HER2+ vs. HER2-
Gene name HER2+ (N = 23) Ave. counts HER2+ (N = 19) Ave. counts Log2 fold diff. (HER2+. vs. HER-) P value FDR
hsa-miR-885-3p 32 160 -2.31 2.05E-10 1.13E-07
hsa-miR-122 98, 310 464, 256 -2.24 3.08E-10 1.13E-07
hsa-miR-375 17, 052 3, 977 2.10 1.72E-08 4.74E-06
hsa-miR-184 128 35 1.88 5.72E-07 1.05E-04
hsa-miR-1228* 65 166 -1.35 1.32E-04 7.62E-03
hsa-miR-483-5p 194 484 -1.32 1.60E-04 8.80E-03
hsa-miR-429 193 75 1.37 1.81E-04 9.48E-03
hsa-miR-205 189 80 1.23 7.03E-04 3.14E-02
hsa-miR-217 49 106 -1.12 1.41E-03 5.00E-02
Inflammatory vs. Non-inflammatory
Gene name Inflam. (N = 10) Ave. counts Non-inflam. (N = 32) Ave. counts Log2 fold diff. (Inflam. vs. Non inflam.) P value FDR
hsa-miR-375 35, 465 3, 535 3.33 3.76E-20 4.14E-17
hsa-miR-184 267 29 3.18 5.28E-18 2.90E-15
hsa-miR-196a 1217 195 2.64 3.62E-13 1.33E-10
hsa-miR-429 341 77 2.15 4.14E-09 5.69E-07
hsa-miR-200a 811 206 1.98 6.26E-08 7.65E-06
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from 6-1, 097 counts with an average of 61, and miR-
410, ranged from 1-1, 620 counts with an average of
220). For PCR analyses, levels of miR-16, which were
consistent among all samples (Additional file 2: Table
S2), and reportedly used as the internal control for cir-
culating miRNAs in previous PCR-based studies [22,24],
were used as the reference for data normalization. Our
results indicated that gene-specific PCR could detect
miRNA with as few as 20 counts in a sample (data not
shown), and the low-abundant miR-184 and miR-410
could be detected from ~90% of all tested samples (29
out of 32). Pairwise Pearson correlation was calculated
to determine the consistency of the miRNA levels deter-
mined by deep sequencing (normalized log2 counts and
PCR-determined levels relative to miR-16) in each sam-
ple. For all tested miRNAs, significant (P < 0.05) corre-
lations were observed between the two methods
(Additional file 1: Figure S2).
We further focused on miR-375 and miR-122, two
miRNAs with the most significant fold differences in the
associations with metastatic relapse and NCT response
(Table 1). Consistent with the deep sequencing results,
lower levels of miR-375 and higher levels of miR-122
detected by PCR both significantly correlated with dis-
ease relapse in all patients and with resistance to NCT
(non-pCR) in HER2
+ patients (Figures 2 and Additional
file 1: Figure S3). These data indicated the feasibility of
cost-efficient PCR assays of these two genes to poten-
tially predict clinical outcome of locally advanced BCs.
Levels of other miRNAs examined by PCR did not show
significant differences in the comparisons for disease
relapse and NCT response (data not shown).
Prediction of relapse by circulating miR-375 and miR-122
We next evaluated the sensitivity and specificity of the
two circulating miRNA markers we identified, i.e., miR-
375 and miR-122, in predicting metastatic relapse in our
NCT study cohort using leave-one-out cross validation
(See method section for details). Results indicated that
both circulating miR-375 and miR-122 could predict
metastasis with relatively high sensitivity and specificity,
and the miR-375/miR-122 two-gene signature
demonstrated the best predicting performance, with a
sensitivity of 80% and specificity of 100% (Table 3).
Circulating miR-122 predicts metastasis in an
independent cohort of early-stage BCs
We further assembled an independent validation
cohort of 26 stage II-III BC patients, including 8
patients with metastatic recurrence within 2 years after
initial diagnosis, as well as appropriate controls with
matched clinical parameters but without disease recur-
r e n c e( A d d i t i o n a lf i l e1 :T a b l eS 1 ) .S e r u mR N Aw a s
isolated and subjected to qRT-PCR to detect levels of
miR-375, miR-122 and miR-16. Upon normalization to
miR-16, circulating miR-122 levels were significantly
higher in the group with relapse (P = 0.0294), and
could predict metastasis at a sensitivity of 88% and
specificity of 78% in this cohort (Figure 3 and Table
3). Levels of miR-375, however, were not significantly
Figure 2 PCR-determined levels of miR-375 and miR-122 are
associated with clinical outcome. Levels of miR-375 and miR-122
were measured by PCR and normalized to the level of miR-16 in
each sample. Comparisons were carried out between the two
groups of relapsed vs. non-relapsed (A) or pCR vs. non-pCR (B). For
each group, mean and the standard error of the mean (SEM) are
indicated. T-tests were performed between the two groups and P
values are indicated.
Table 2 Circulating miRNAs associated with histopathological features of BC* (Continued)
hsa-miR-200c 3, 714 1, 033 1.85 4.22E-07 4.65E-05
hsa-miR-3065-5p 86 29 1.56 3.11E-05 3.45E-04
hsa-miR-141 1, 571 597 1.40 1.44E-04 7.19E-03
hsa-miR-203 403 155 1.38 1.93E-04 8.85E-03
hsa-miR-200b* 89 36 1.33 3.90E-04 1.59E-02
hsa-miR-1308 5, 332 2, 358 1.18 1.35E-03 4.96E-02
*FDR < 0.05
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groups (Table 3 and data not shown), possibly due to
the fact that patients in the validation cohort were
generally lower stage at diagnosis, with more hormone
receptor positive disease, and more frequently overex-
pressed HER2 (Additional file 1: Table S1). In addition,
they received diverse therapies seen in a general oncol-
ogy practice. Because the status of ER/PR and HER2 in
primary BCs have been historically linked to clinical
outcomes [30,31], we also computed the sensitivity and
specificity of each histopathological parameter in asso-
ciation with development of metastatic relapse in the
testing cohort. Results indicated that, in comparison to
the histopathological parameters, circulating miR-122
served as a better predictor of metastasis, regardless of
the heterogeneity of this cohort (Odds Ratio 24.5; P <
0.01; Additional file 1: Table S4).
Discussion
Using a comprehensive de novo sequencing approach,
we identified sets of circulating miRNAs that were asso-
ciated with various clinicopathological parameters and
clinical outcome in stage II-III BC patients. Previous
studies have linked higher circulating levels of miR-10b
and miR-21 to negative ER status [22], and higher circu-
lating levels of miR-155 to positive PR status [25]. None
of these miRNAs exhibited correlations with ER/PR sta-
tus in our study, possibly due to the differences of the
size, composition of study cohorts, and/or treatment
regimens. We observed that two miRNA clusters, miR-
200b-200a-429 and miR-200c-141, were significantly
associated with negative ER status and inflammatory BC
(Tables 2 and Additional file 3: S3). In addition, we
found that several miRNAs, including miR-375, miR-
429, miR-196a, miR-370, miR-125a-5p, and miR-224,
simultaneously correlated with both ER and PR status in
the same direction (Table 2). Among these miRNAs,
miR-375 and miR-429 also correlated with HER2 status
but in the opposite direction as compared to their corre-
lations with ER/PR status (Table 2). Expression of these
miRNAs in primary BCs and their functional links with
ER/PR/HER2 merit additional investigation, and may
further elucidate the pathogenic mechanisms of these
long-known receptors in BC.
We also identified a two-gene signature consisting of
miR-375 and miR-122 with the capacity to predict disease
relapse in our study cohort of stage II-III BC patients who
Table 3 Performance analysis among training and testing cohorts
Training Cohort (N = 32)
Predictor Predicted Relapse Predicted Non-relapse Sensitivity Specificity
Circulating miR-375 Observed relapse 9 1 9/10 (90%) 20/22 (91%)
Observed non-relapse 2 20
Circulating miR-122 Observed relapse 4 6 4/10 (40%) 11/22 (50%)
Observed non-relapse 11 11
375/122 two-gene signature Observed relapse 8 2 8/10 (80%) 22/22 (100%)
Observed non-relapse 0 22
Training Cohort (N = 26)
Predictor Predicted Relapse Predicted Non-relapse Sensitivity Specificity
Circulating miR-375 Observed relapse 0 8 0/8 (0%) 11/18 (61%)
Observed non-relapse 7 11
Circulating miR-122 Observed relapse 7 1 7/8 (88%) 14/18 (78%)
Observed non-relapse 4 14
375/122 two-gene signature Observed relapse 2 6 2/8 (25%) 17/18 (94%)
Observed non-relapse 1 17
Figure 3 Circulating miR-122 predicts metastatic relapse in an
independent BC cohort. Levels of serum miR-122 in an
independent validation cohort of 26 stage II-III BC patients were
measured by PCR and normalized to the level of miR-16 in each
sample.
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dation set derived from an observational cohort, circulat-
ing miR-122, but not miR-375, remained as a predictor of
metastasis (Figure 3). Interestingly, both miR-375 and
miR-122 correlated with HER2 status (Table 2), with
higher levels of miR-375 and lower levels of miR-122 asso-
ciating with positive HER2 status (Table 2), pCR to NCT
(Figure 2B), and absence of relapse (Figure 2A). Consistent
with previous observations that HER2
+ BCs have higher
rates of pCR to NCT [30], these results raise interesting
questions to be addressed in future studies. For example,
the origin of circulating miRNA is still unclear. It has been
proposed that tumor-associated miRNAs can be released
into the bloodstream when tumor cells are dying and
being lysed [22,32], or through active secretion of miRNA-
loaded exosomes by tumor cells [20]. Furthermore, the
cellular source of circulating miR-375 and miR-122
remains unknown; their presence may reflect expression
in the primary tumor or in other cell types, such as
immune cells.
MiR-122, the circulating miRNA that consistently pre-
dicted metastasis in both our study cohort and validation
cohort, is the most frequent miRNA isolated in the liver
and is involved in the regulation of lipid metabolism [33].
Downregulation of miR-122 has been reported in hepato-
carcinoma (HCC) [34]. In contrast, higher levels of miR-
122 in circulation correlate with HCC [35] and liver injury
[36]. Expression of miR-122 has also been reported in pri-
mary fibroblasts, where the miRNA is involved in p53
mRNA polyadenylation/translation by targeting the cyto-
plasmic polyadenylation element binding protein (CPEB)
[37]. Expression and function of miR-122 have not yet
been reported in BC. Our results here, however, strongly
suggest a role of miR-122 in BC progression, an area of
study currently under investigation in our laboratory.
Roth et al. report that circulating levels of miR-10b,
miR-34a and miR-155 correlate with the presence of
overt metastases in BC patients [24]. These miRNAs,
however, did not significantly correlate with metastatic
relapse in our retrospective study in stage II-III patients.
It is possible that the change of circulating miR-10b,
miR-34a and miR-155 levels occurs after cancer dissemi-
nation, whereas levels of circulating miR-122 and miR-
375, as identified herein, start to change and reflect
metastatic potential at an earlier stage of disease. Valida-
tion using a larger patient cohort will be necessary in
future studies. Findings will allow us to further refine a
circulating miRNA signature that can predict metastasis
and guide individualized adjuvant and neoadjuvant ther-
apy to minimize risk of systemic relapse.
Conclusions
Using a comprehensive de novo sequencing approach,
we identified sets of circulating miRNAs that were
associated with various clinicopathological parameters
and clinical outcome in stage II-III BC patients. We
also identified a two-gene signature consisting of miR-
375 and miR-122 with the capacity to predict disease
relapse in our study cohort of stage II-III BC patients
who received identical NCT regimens. In a heteroge-
neous validation set derived from an observational
cohort, circulating miR-122, but not miR-375,
remained as a predictor of metastasis. These results
may allow optimized chemotherapy treatments and
preventive anti-metastasis interventions in future clini-
cal applications.
Additional material
Additional file 1: Figure S1Composition of small RNA sequences in
a representative serum sample. Total sequence reads obtained from
deep sequencing were aligned to human genome database NCBI36/
hg18. The percentage of each class of small RNAs was indicated in the
pie chart. scRNA: small cytoplasmic RNA; snRNA: small nuclear RNA;
snoRNA: small nucleolar RNA; mt-tRNA: mitochondrial tRNA.
Additional file 2: Additional file 2: Table S2. Normalized counts of all
miRNAs in the circulation.
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